Yuzuru Sasamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuzuru Sasamoto has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Akash Sabarwal
Boston Children’s Hospital 1 Division of Nephrology Boston, Massachusetts
1 shared publication - Chiranth Prakash
Boston Children’s Hospital 1 Division of Nephrology Boston, Massachusetts
1 shared publication Kosei Suzuki
Department of Ophthalmology, University of Washington, Seattle, WA, United States
1 shared publication- Laxminarayan Rawat
Boston Children’s Hospital 1 Division of Nephrology Boston, Massachusetts
1 shared publication Markus H. Frank
Transplant Research Program, Boston Children's Hospital, Boston, MA, United States; Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA; School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia
1 shared publication- Natasha Y. Frank
Brigham and Women's Hospital
1 shared publication
Latest Publications
- 16 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF14
Inhibition of PLK1 Helps Restrict c-Met–Induced Growth and Therapeutic Resistance of Renal Cancer Cells
Acquired therapeutic resistance is a major problem in the treatment of advanced renal cell carcinoma (RCC). The receptor tyrosine kinase (RTK) c-Met is hyperactive in RCC and plays a major role in the survival of tumor cells during therapy-induced oxidative stress. Although the c-Met/RTK inhibitor cabozantinib (cabo) has demonstrated efficacy in the treatment of RCC, therapeutic resistance significantly restricts its effectiveness. Thus, new target molecules and combination therapies need to be explored. Among several cell-cycle regulators, Polo-like kinase 1 (PLK1), which is overexpressed in RCC, can play a vital role in cancer progression. In this study, for the first time, we show that the activation of c-Met markedly promotes renal cancer cell growth and proliferation through PLK1. We found that a novel combination treatment with cabo and a PLK1 inhibitor (onvansertib) induces dual-phase cell-cycle arrest at both G1 and G2–M checkpoints and impairs RCC cell migration. It induces tumor cell apoptosis by downregulating the antioxidant transcription factor/cytoprotective molecule Nrf2/heme oxygenase-1 and inducing oxidative stress. Our results also showed that onvansertib can downregulate ATP-binding cassette transporters that are involved in drug resistance, and it resensitizes cabo-resistant RCC cells to apoptotic cell death. We further confirmed the effectiveness of the combination treatment through 3D spheroid culture as well as tumor xenograft models of RCC. Following combination treatment, there was increased drug-induced cytotoxicity and markedly reduced tumor growth in vivo. Together, our preclinical study identifies that cabo + onvansertib is an effective combination treatment to overcome c-Met–induced therapeutic resistance in RCC with translational potential.
- 16 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF14
Inhibition of PLK1 Helps Restrict c-Met–Induced Growth and Therapeutic Resistance of Renal Cancer Cells
Acquired therapeutic resistance is a major problem in the treatment of advanced renal cell carcinoma (RCC). The receptor tyrosine kinase (RTK) c-Met is hyperactive in RCC and plays a major role in the survival of tumor cells during therapy-induced oxidative stress. Although the c-Met/RTK inhibitor cabozantinib (cabo) has demonstrated efficacy in the treatment of RCC, therapeutic resistance significantly restricts its effectiveness. Thus, new target molecules and combination therapies need to be explored. Among several cell-cycle regulators, Polo-like kinase 1 (PLK1), which is overexpressed in RCC, can play a vital role in cancer progression. In this study, for the first time, we show that the activation of c-Met markedly promotes renal cancer cell growth and proliferation through PLK1. We found that a novel combination treatment with cabo and a PLK1 inhibitor (onvansertib) induces dual-phase cell-cycle arrest at both G1 and G2–M checkpoints and impairs RCC cell migration. It induces tumor cell apoptosis by downregulating the antioxidant transcription factor/cytoprotective molecule Nrf2/heme oxygenase-1 and inducing oxidative stress. Our results also showed that onvansertib can downregulate ATP-binding cassette transporters that are involved in drug resistance, and it resensitizes cabo-resistant RCC cells to apoptotic cell death. We further confirmed the effectiveness of the combination treatment through 3D spheroid culture as well as tumor xenograft models of RCC. Following combination treatment, there was increased drug-induced cytotoxicity and markedly reduced tumor growth in vivo. Together, our preclinical study identifies that cabo + onvansertib is an effective combination treatment to overcome c-Met–induced therapeutic resistance in RCC with translational potential.
- Open Access
- 13 May 2026
- Published by Elsevier in Experimental Eye Research
- Vol. 269, 111059
YAP1-dependent regulation of cell size in BCAM-positive limbal corneal progenitor cells
- 13 May 2026
- Published by Elsevier in Experimental Eye Research
- Vol. 269, 111059
Open AccessYAP1-dependent regulation of cell size in BCAM-positive limbal corneal progenitor cells